For example, KRAS mutations, which are present in 45% of EC, 30% of OC, and 20% of cervical cancers, often lead to continuous signaling through the KRAS pathway, even in the absence of upstream growth factor stimulation [11]. This evidence concerns the gene KRAS and cervical carcinoma.